He has more than three years of expertise in the drug discovery field. His primary responsibilities have been validating targets, developing de novo HTS assays and following up hit compounds through their optimization until reaching preclinical development. His experience spans different therapeutics areas as cardiology and oncology.
Before joining Dewpoint Therapeutics, Jordi worked in ZeCardio Therapeutics running and validating compound screens and generating cardiovascular disease models with CRISPR/Cas9 in vivo using zebrafish and in cellulo to develop screening campaigns. Afterwards, he joined the talented oncology team at Dewpoint therapeutics to explore the biology of condensates and find novel compounds.
Jordi holds a Bachelor of Science degree in Chemistry with a specialization in Biological Chemistry from the Autonomous University of Barcelona and a Master of Science degree in Bioengineering from the university Institut Químic de Sarrià.